### Accepted Manuscript

Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress

Mahmoud El-Daly, Vivek Krishna Pulakazhi Venu, Mahmoud Saifeddine, Koichiro Mihara, Sean Kang, Paul W.M. Fedak, Laurie A. Alston, Simon A. Hirota, Hong Ding, Chris R. Triggle, Morley D. Hollenberg

vascular pharmacology and was stated and the cate of t

PII: S1537-1891(18)30057-0

DOI: doi:10.1016/j.vph.2018.06.006

Reference: VPH 6490

To appear in: Vascular Pharmacology

Received date: 3 February 2018
Revised date: 5 May 2018
Accepted date: 9 June 2018

Please cite this article as: Mahmoud El-Daly, Vivek Krishna Pulakazhi Venu, Mahmoud Saifeddine, Koichiro Mihara, Sean Kang, Paul W.M. Fedak, Laurie A. Alston, Simon A. Hirota, Hong Ding, Chris R. Triggle, Morley D. Hollenberg, Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. Vph (2017), doi:10.1016/j.vph.2018.06.006

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **ACCEPTED MANUSCRIPT**

Hyperglycaemic Impairment of PAR2-mediated Vasodilation: Prevention By Inhibition Of Aortic Endothelial Sodium-Glucose-Co-Transporter-2 and Minimizing Oxidative Stress

Running Title: Preventing hyperglycaemic ROS-induced vascular dysfunction

Mahmoud El-Daly<sup>a,f#</sup>, Vivek Krishna Pulakazhi Venu<sup>a,b#</sup>, Mahmoud Saifeddine<sup>a,b</sup>, Koichiro Mihara<sup>a,b</sup>, Sean Kang<sup>d</sup>, Paul W. M. Fedak<sup>d</sup>, Laurie A. Alston<sup>a,b</sup>, Simon A. Hirota<sup>a,b</sup>, Hong Ding<sup>e</sup>, Chris R. Triggle<sup>b,e</sup> and Morley D. Hollenberg<sup>a,b,c,\*</sup>

<sup>a-d</sup>University of Calgary Cumming School of Medicine, Calgary AB Canada T2N 4N1,

<sup>a</sup>Inflammation Research Network-Snyder Institute for Chronic Disease,

<sup>b</sup>Department of Physiology & Pharmacology,

<sup>c</sup>Department of Medicine,

<sup>d</sup>Section of Cardiac Surgery, Department of Cardiac Science, Libin Cardiovascular Institute

<sup>e</sup>Departments of Pharmacology and Medical Education, Weill Cornell Medicine in Qatar

<sup>f</sup>Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, Minia Egypt (M. El-D.). # Authors who made equal Contributions

Category - Cardiovascular Pharmacology

#### \* Corresponding Author:

Morley D. Hollenberg

Department of Physiology & Pharmacology,

University of Calgary Cumming School of Medicine,

3330 Hospital Drive NW, Calgary AB,

Canada T2N 4N1

Email: mhollenb@ucalgary.ca

Phone: 403-669-6954

Fax: 403-270-0979

Text pages: 25

**Abstract:** 226 words

Figures: 12

#### Download English Version:

# https://daneshyari.com/en/article/8950178

Download Persian Version:

https://daneshyari.com/article/8950178

<u>Daneshyari.com</u>